Pathnostics
7
0
0
4
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 100/100
42.9%
3 terminated/withdrawn out of 7 trials
57.1%
-29.4% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 4 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (7)
Diagnosis, Antibiotic Prescribing Practices and Outcomes of cUTI in an Outpatient Setting
Role: lead
Evaluating UTI Diagnosis in Nursing Homes
Role: lead
Evaluating UTI Outcomes in at Risk Populations
Role: lead
Morbidity Rate for UTI Through Use of PCR-Based Diagnosis and Management
Role: lead
Comparison of Pre-procedural PCR and Culture-based UTI Assessment Prior to Intravesical Botox Injection
Role: lead
Rapid Molecular Organism Identification and Mixed Flora Antibiotic Resistance Profiling (MixAR) Prospective Study
Role: lead
Shifts in the Respiratory Microbiome and Clinical Outcomes of SARS-CoV-2
Role: lead
All 7 trials loaded